AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com
The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
- The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
- Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
- The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
- The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.